us. are where Please potential the I turn today's thanks so a of about for we're to of Good why start with everyone, afternoon, joining call business. we want X. and to creation our overview Mark. Thanks, and value excited Slide level high
Over expanded of attracted talent from developed introducing billion industry orthopedics. have and $X we market and and differentiated segments three the largest our to into billion We've leading are $X solutions we've plus. market last fastest the in the years, growing now addressable
As year to at Medicine, a and Arthroplasty limited market execute beginning the excited energized of enter new system. an very cornerstone execution balance number our a full teams continued release made and product RevoMotion well. the are team, market And phase into this moved next strategic Reverse release alone, with path We've we strong investments year. of initiated about sheet portfolio expanded we last this ahead. we Sports this just X-Twist, our of our Shoulder the of just in and
development based We filed significant hyaluronic FDA cuff XXX(k)s, multiple the our and system. regenerative completed rotator patch for acid
the build we that coming our trial next in pain completed enrollment following we Anika, for targets over towards point our of engaging Phase Cingal III growth XXXX the quarter FDA the Hyalofast the for repair with process We generation endpoints and pivotal an the met have III inflection trial. Phase last nearly news exciting clinical are on cartilage we the as of OA accelerated is our years. therapy,
get into specifics. me let more Now
headwinds short single outside the continue supply revenue we Anika by our of hyaluronic in the performance OA even the As U.S. for treat strong XX% injection delivered the internationally. continues Slide to Monovisc the through Also X% pain. a Orthovisc with and generation quarter sustained to up fourth chain be financial full with both the X, and be year. non-opioid next the growth on with acid-based OA long-term you pain leader management we can and Cingal, see year, product for excited U.S., to and market in
Mitek our tremendous viscosupplement one Cingal J&J in partnership Through share long-term opportunity U.S., the we and strengthened market a have market. for with position for is Orthovisc Monovisc U.S. the Anika. our number in
successfully have the commercialized and and of generation pain in more We realizing osteoarthritis more States, United more where countries Cingal this clinicians next XX OA than are benefits their patients outside product. the
approval continuing commercial recently U.S. international our clinical advance we're -- success III towards and data, towards to its reported FDA Phase exciting in USA Cingal Given the
our based launches. business product through will we XXXX preservation accelerate move joint its growth of the expect recent We on our as strength
the receiving we great still are about with up revenue detail in the targeting XXXX of discuss year, continues of solutions in we're this regenerative for expansion, early products we're that Anika's are rapidly share launched which surgeons feedback benefits growing capture Tactoset from the differentiated success the While stages, we given Tactoset we'll more further shortly. full XX% market to in products. platform,
the release thrilled we quarter full last demand. third into Following meet year, in be of to launch in late XXXX. early the of moved positioned successful limited We're to X-Twist
constrained feedback Now challenges positive its X-Twist to supply Medicine its continues that that past initial limited be during variety a of Sports as applications. highlight using they launch in have we confidence the last growth they it chain the are in year. Surgeon
that the other other facilitates in soft accommodate. design ankle, and has We've the surgical to them repairs on are received extremities procedures systems and X-Twist our given that also unable and shoulder, great tissue foot feedback across versatility that
the RevoMotion commenced recently Reverse of system. release Shoulder market we our limited new addition, In
in early With the performed surgeries XXXX. first
RevoMotion shoulder, significantly arthroplasty fantastic. from and early expands the surgeons release portfolio our limited been feedback has
our $XXX this U.S. The largest market product of shoulder segment. on further market. the reverse million and segment the entrance growing the shoulder fastest into replacement As growing rapidly I'll slide, marks launch discuss next
Hyalofast that been the access prioritized has to enable by new to report patients a as Allowing to review therapies. pleased also Device and interaction I'm Breakthrough designated for FDA. faster
is requires Hyalofast reminder, a cartilage off-the-shelf repair single that bone a differentiated is product and highly preserving. As surgery our only
we our to track PMA in XXXX. in file Phase FDA full XXX XXX pivotal III Hyalofast remain clinical subjects on enrolled approaching a with having now the for enrollment are trial We and Hyalofast of
in Finally, U.S. other we medical meetings. XXX orthopedic activities made training in alone, XXXX, more training in at to the person conducting for our program addition than in in tremendous progress global surgeons education
programs and practice as into enhancing procedural for return integrate their education patients and surgeons our technical medical products active Our are they confidence their our to living.
shoulder Let's highly turn a a Slide efficiency. like bit enhanced I'd to and the our designed system, and of where launch RevoMotion innovative OR expand specifically to System. X, RevoMotion for Shoulder recent the is Reverse ASC differentiated reverse on
which threaded with in the anatomy match On implant RevoMotion glenoid humeral portfolio. baseplate, glenoid enhances flexibility. It also designs that native preserving side, to industry's our arthrosurface other smallest and patient implant diameter personalization similar the intraoperative the bone offers provides designs
instrument Some reprocessing reducing this the cost side a of for instrument limiting volume the tray are design, our relative on and with system of instrumentation most the streamlined two customers. and friendly, is sterile both consolidated exciting features hospital ASC
four to In of hospital to and competitive require ASC systems instruments, efficiency use trays fact, systems most in a makes to the difficult major between six those setting. burden which presents
x-rays. launch, post-op this this of and with the momentum visits are we the more full to end We've are pleased received ahead the that very which great is commenting early post-op feedback conserving extremely year. importantly, look much following towards Most their first building efficient. system We a surgeons surgeries are well forward bone in doing targeting patients on with RevoMotion that of and surgeons is
our minutes spend pipeline. development a like I'd few Now product to reviewing new
and our As Slide X-Twist, the now with motion, and beginning incredibly augmentation, Anika our you These most product Tactoset wrist our X, introductions has strategy in launches targets. growth key NPD achieving including can to with successful see multiyear RevoMotion. new on total been work are product productive several XXXX, recently
our By that market Anika ASC and procedures, are continuing and brings launching the settings. our Tactoset platform. remain on value focused Solutions products categories across these we portfolio, to new both innovative expand enhance hospital In to our we Regenerative opportunity and the advancing
which have indications since and XXX(k)s expand late in the XXXX. on process, allow us We build this further we've had commercial to in multiple success launching will
the creating of market $XXX augmentation. a can Tactoset market with to hardware the new franchise, continued well for the that believe expansion the we by We million beyond increase addressable
Following the $XXX and market technology as platform ankle to plus procedures million we a Anika rotator high cuff as the Sports to and of of addition it such portfolio surgeons is the performing Sports a design cornerstone X-Twist, full stabilization. leverage look With positioned repairs become a needs believe market X-Twist U.S. release volume Medicine to true address Anika to we its is has products. opportunity, the future potential Medicine in
acid but we our designed is be will provide shoulder our capacity augmentation that compared data first hyaluronic patches year healing for Anika's the support a next to generation patch regenerative not tears. and that is launching further the only to strengthen the stronger, rotator for that is the cuff patch initially also mechanically to market. to on regenerative It shows portfolio. will differentiated improved system based We're shoulder with collagen growing the pleased announce tendons preclinical
share methods, once at been submissions of promises up arthroscopic the game and with end and our and Along XXX(k) about cleared system gearing to details for first We truly product we're multiple be has changer. surgeries. the the additional completed delivery a XXXX the fixation we'll system
attractive market be beyond will opportunities we for key growth. expansion the shoulder has driver system the Given for patches, regenerative and this a believe
market. growth believe the has million. potential U.S. are augment important off-the-shelf and significant market approved available sized addressable it will term significant its is they enable two through Due longer $XXX concretively the that market at will forward FDA. an further least look opportunities which market progress have about we We U.S. reach with and Hyalofast and and also stage Hyalofast single Hyalofast differentiation, making potential We're a great to that that advancing are have expanding advancing we Hyalofast for Finally, to to solution. Cingal Anika's its to that reinforce once given excited we be us
international XX OA Cingal the market towards continuing true clinical In our and it key commercialization. revenue for pain U.S. quarter, weeks. come. over strong become alone for also superiority could steroid advance that potentially for believe space successfully non-opioid its double a at in OA the to a is Anika years We're addressable data, and we performance engine announced pain next reduction demonstrated it pain to we given generation and Cingal third product total
exploring the will look select and regulatory As Asian with to parallel, regarding potential the Cingal partnerships to we through In we continue are engage for U.S. next in steps advance U.S. markets. FDA commercial approval. ahead, we
options Cingal we drive best intend a proceed as rights Anika controls reminder, global and around As our and osteoarthritis world value. thoughtfully we shareholder full patients for evaluate to the to Cingal commercialize to serve
important the We will this continue provide coming to make we updates quarters progress as asset. strategic over on
briefly our reflect on come. I to to quarter, opportunity an far last to Similar how want has as Slide use X business
within spaces opportunity to into As expand orthopedics. markets growing continue that high and we large represent
past the years, than to Over Anika's more $X billion opportunity expanded $X have from three today. we billion market
In and higher Cingal addition medicine joint investing comprehensive to advancing solutions. grown growth through and build solutions, to highly evolved our areas development, yet in have a we sports joint portfolio complementary regenerative in arthrosurface preservation actively clinical portfolio,
segments are growing opportunity. by a particularly representing Moving $X continuum preservation on fastest billion the to cuff the of rotator and Slide we the across joint market disease targeting shoulder, X, largest the market of focusing U.S.
Anika's recent proprietary unique using launches product portfolio continuum. specifically Our the that includes address technologies shoulder and
hardware. look become on looking Tactoset continuing its the as future side, slide, upper potential Then in clockwise, design X-Twist augment to we technology offer leverage right of the true we hand the platform to a regenerative has we corner to First, products. the believe to
Specifically with differentiated strong suture quality repair. when solution poor a to surgeons achieve anchors to a encounter bone provide
cuff now the in providing In X-Twist. have system, we procedures, are patch pipeline sell is to the And cuff augmentation Tactoset we our rotator cross rotator more regenerative with that opportunity design. in alongside a shoulder foundation in adding bone enables strong preserving joint replacement and access the to a And a differentiated focus regeneration Tactoset. market RevoMotion with full finally, the on
will now ASC arthroplasty for spectrum address in shoulder the of portfolio full surgeons our settings. and hospital the means This needs
total solutions major specifically product dramatically we Now shoulder drive the over enhanced. motion filled, that category our our have products joint is this opportunity Arthrosurface to
deliver to be X-Twist augmented that significant our be preservation which in Anika will regenerative drivers expect further RevoMotion joint We growth XXXX. XXXX, growth and in double-digit by restoration patch in system will and positioning
quarter fourth Mike? now over results of year XXXX and turn outlook. I'll to for end our it Mike a review and
